Document Detail

A Naturalistic Comparison of the Long-Term Metabolic Adverse Effects of Clozapine Versus Other Antipsychotics for Patients With Psychotic Illnesses.
MedLine Citation:
PMID:  24943389     Owner:  NLM     Status:  Publisher    
OBJECTIVE: Clozapine, an evidence-based treatment of refractory schizophrenia, is associated with increased weight gain and metabolic dysregulation compared with most antipsychotics in short-term clinical trials. However, there are limited data describing comparative long-term metabolic risks. In this report, we examined whether short-term differences persist with long-term exposure to clozapine.
METHODS: The data of all patients in a university-based clinic with a psychotic illness or a mood disorder with psychotic features, based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis, and treated with an antipsychotic in calendar year 2012 were examined. A total of 307 patients met the criteria; 96 patients were treated with clozapine and the remaining 211 patients were treated with 1 or more non-clozapine antipsychotics. Body mass index, type 2 diabetes, hypertension, dyslipidemia, and obesity were compared.
RESULTS: The mean duration of the clozapine treatment was 7.6 years (range, 2 months to 21 y). On all metabolic measures, there were no statistically significant differences between the clozapine and non-clozapine groups (mean body mass index, 31 vs 32; type 2 diabetes, 17% vs 18%; dyslipidemia, 35% vs 38%; hypertension, 32% vs 39%; and obesity, 48% vs 54%). Removing the olanzapine-treated patients (n = 51) from the non-clozapine group did not change the findings.
CONCLUSIONS: In this university-based clinic sample with a large number of clozapine-treated patients, we found no evidence of increased risk in any individual measure for those receiving clozapine. Although speculative, the relative contribution of the increased short-term metabolic risk associated with clozapine may be diminished over time because multiple other variables likely also impact metabolic risk during the life span. Although speculative, the relative contribution of the increased short-term metabolic risk associated with clozapine may be diminished over time due to the accumulated impact of other variables that also impact metabolic risk across the life span.
Anne C Kelly; Brian B Sheitman; Robert M Hamer; David C Rhyne; Robin M Reed; Karen A Graham; Shane W Rau; John H Gilmore; Diana O Perkins; Susan Saik Peebles; Carol J VanderZwaag; Lars Fredrik Jarskog
Related Documents :
23015559 - Does obesity influence clinical outcome at nine years following total knee replacement?
22503179 - Evolution of treatment for traumatic thoracic aortic injuries.
22551649 - Coronoidectomy, masticatory myotomy and buccal fat pad graft in management of advanced ...
15449249 - Critical pathways can improve results with carotid endarterectomy.
24837559 - Experience of excess skin after gastric bypass or duodenal switch in patients with supe...
23856989 - Assessment of the effect of bariatric surgery on obstructive sleep apnea at two postope...
11868009 - Features of malignant biliary obstruction affecting the patency of metallic stents: a m...
6849189 - Employment following peripheral vascular surgery: an increasingly critical issue.
8092769 - Urinary tract fistulas following abdominal hysterectomy.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-6-17
Journal Detail:
Title:  Journal of clinical psychopharmacology     Volume:  -     ISSN:  1533-712X     ISO Abbreviation:  J Clin Psychopharmacol     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-6-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8109496     Medline TA:  J Clin Psychopharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of Low-Dose Olanzapine on Duloxetine-Related Nausea and Vomiting for the Treatment of Major ...
Next Document:  Prescription Patterns of Psychotropic Medications for the Treatment of Psychotic Disorders in the La...